Abstract
Fluorescent imaging has been widely used in the detection of diseases, especially cancer. Among them, biomarker-specific ligand-based imaging strategies have attracted much attention, due to their improved image contrast and diagnostic accuracy. In this work, an HSP90 inhibitor based fluorescent probe (Probe 1) was synthesized possessing the potential of selective tumor targeting, which was constructed with an HSP90 inhibitor and 4-hydroxy-1,8-naphthalimide derivative. Probe 2, a resorcinol-blocked probe was also synthesized as a control, which prevented binding with the HSP90 ATP binding pocket. Biological studies showed that Probe 1 could be selectively accumulated by tumor cells, while Probe 2 not, suggesting that Probe 1 is a promising targeted tumor imaging agent for early diagnosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
